May 11, 2021

How UCB and Basilea overcome the barriers to building effective IP strategies

Pin It

IAM’s third annual Pharma & Biotech IP event

With the prospect of disruptive political and legislative change in Europe and elsewhere, it has never been more important for patent professionals in life sciences to have a nuanced understanding of the issues shaping the future of IP protection and value creation.

At IAM’s third annual Pharma & Biotech IP event, UCB’s Chief IP Officer Stephane Drouin and Basilea Pharmaceutica’s Head of Patents Jonathan Thwaite will be among the many industry-leading professionals sharing their insights on how to tailor IP strategies for commercial and legal success.

View the speaker line up here and full programme here

Across a series of panel discussions and keynote sessions, attendees will receive expert guidance on critical biopharma IP topics, including second medical use patents, the latest case law from the ECJ, legal and commercial challenges in the United States and China, the future of SPCs and the CRISPR IP landscape.

This is your last chance to save £200. Register before 11:59 PM this coming Friday!

Use code* PHABIO200 when you register here.

Print Friendly, PDF & Email
About ieyenews

Speak Your Mind